Citius Pharmaceuticals, Inc. (CTXR) vs Dyadic International, Inc. (DYAI)
A side-by-side comparison of Citius Pharmaceuticals, Inc. and Dyadic International, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CTXR
Citius Pharmaceuticals, Inc.
$0.50HealthcareDelayed quote: Oct 6, 2026, 12:54 PM EDT
DYAI
Dyadic International, Inc.
$0.45HealthcareDelayed quote: Oct 6, 2026, 12:42 PM EDT
Total return — CTXR vs DYAI
growth of $100 · dividends reinvested · last 10yCTXR -99.8% (-46.2%/yr)DYAI -70.5% (-11.5%/yr)DYAI compounded faster over this window
Log scale — wide-divergence pair
CTXR DYAI
CTXR vs DYAI: by the numbers
- •DYAI is the larger company ($16M vs $14M market cap).
- •Both run net losses; DYAI's is the smaller (-219.50% vs -651.27% net margin).
Metrics side by side
Valuation
| Metric | CTXR | DYAI |
|---|---|---|
| P/S ratio | 1.94 | 4.72 |
| P/B ratio | 0.21 | N/A |
Profitability
| Metric | CTXR | DYAI |
|---|---|---|
| Gross margin | 0.00% | -88.25% |
| Operating margin | 0.00% | -579.88% |
| Net margin | -651.27% | -219.50% |
| ROE | -69.47% | N/A |
| ROIC | -67.62% | -279.48% |
Growth (annualized)
| Metric | CTXR | DYAI |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -5.11% |
| Total return CAGR (5Y) | -60.04% | -38.53% |
Frequently asked
- How have CTXR and DYAI total returns compared?
- Over the past 10 years, CTXR delivered -46.34% and DYAI delivered -11.56% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.